SFI
BNTC icon

Susquehanna Fundamental Investments’s Benitec Biopharma BNTC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-633
Closed -$46K – 1705
2021
Q2 		$46K Sell
633
-2
-0.3% -$156 ﹤0.01% 1627
2021
Q1 		$56K Buy
+635
New +$43.2K ﹤0.01% 1491

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PWAC
Private Wealth Advisors (California) Fresno, California $356M AUM 26.22% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Susquehanna Fundamental Investments's BNTC Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Benitec Biopharma (BNTC) in Q3 2021, closing a stake of 633 shares — an estimated $46K sold.

Susquehanna Fundamental Investments first reported a position in BNTC in Q1 2021 and held it in 2 quarters. The position peaked at $56K in Q1 2021. 18 funds tracked by Wall St. Rank hold BNTC as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Benitec Biopharma position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 633 Benitec Biopharma shares in Q3 2021, an estimated $46K.
  • Susquehanna Fundamental Investments first reported a position in Benitec Biopharma in Q1 2021 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Benitec Biopharma position peaked at $56K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.